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Abstract 
Background: This review determined the most commonly used, and reliable, measures 
for assessing clinical outcomes for Multiple Sclerosis (MS). 
Objectives: It was anticipated that this would facilitate the development of a common set 
of metrics, and aid reaching a consensus regarding the outcome measures that are typically used 
in the field of MS clinical research. 
Major Findings: A thorough literature review of clinical outcome measures for MS 
produced 166 measures that have been used in this context. This list was then refined by 
discussion with a panel of consultant neurologists, which reduced the list to 23 commonly 
employed tools. This shortlist was then further refined through surveying 41 centres for MS 
treatment, which reduced the shortlist to 16 measures. The properties of these scales, in terms of 
their symptom/function domains, their specificity for MS, their administration characteristics, 
and their reliability and validity for MS, are all discussed. 
Conclusions: Conclusions regarding the development of potential sets of assessment 
measures for MS, that encompasses broad symptom/function domains, and which are sensitive to 
the practical requirements of administration within clinical contexts, are explored.   
 
Key Words:  Assessment Sets; Multiple Sclerosis; Narrative Review; Outcome Measures; 
Psychometric Properties.  
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Introduction 
Multiple Sclerosis (MS) is a chronic condition of the central nervous system
1,2
. Although a 
central database for MS in the U.K. is being piloted
3-5
, there are currently no definitive figures 
regarding those it affects. Estimates suggest that anywhere between 70,000 and 100,000 people 
in the U.K. have MS
6-8
. MS is most often diagnosed between the ages of 20 and 40 years, 
although it can be diagnosed earlier or later in life
3,6
, and it appears to be one of the most 
common disabling neurological diseases among young adults
9
. MS is a complex condition that 
presents a wide spectrum of severities, symptoms, and impacts on functioning; the neurological 
damage impacts on physical
10-12
, cognitive
13-15
, and psychological and emotional
16-18
 functioning, 
as well as on quality of life
19-21
. In order to enhance medical practice in diagnosis, care, and 
treatment, it is important to determine which measures are best employed in the assessment of 
MS symptoms/functions and clinical outcomes
22,23
. This topic has recently been the subject of 
some study and debate in the context of clinical outcomes
22,23
, and any databases or and 
registries aiming to further knowledge about MS clearly require strong measures at their cores
23
. 
In fact, recently, some such databases have been criticised on the basis of the measures 
selected
24
. The questions, raised by numerous task forces concerned with MS over the last two 
decades about the best set of measures for clinical outcomes for MS that can detect changes in 
impairment and evaluate a person’s MS symptoms and functioning, remain largely 
unanswered
22,25
. 
 
There are numerous measures available for the study of MS
26
, and a number of reviews of these 
assessment instruments have previously been conducted
20,22,27-34
. These reviews highlight several 
commonly used instruments, as well as outlining their properties. However, these reviews are not 
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always comprehensive in their coverage of the literature, frequently focusing on only a few 
selected measures. They do not always address the full range of MS symptomatology or all 
aspects of a person’s functioning, focussing instead on only one specific aspect of MS28,32,34,35. 
Previous work does not always attempt to define standard and comprehensive packages of 
measures to encompass all aspects of MS (i.e. physical, cognitive, psychological and emotional, 
and quality of life functions), although this is increasingly recognised as an important step
36,37
. 
Moreover, with a few exceptions
38
, often previous review articles do not account for typical 
clinical-care usage, but rather are inclined to be research-oriented in outlook
12,32
. 
 
The review that is reported here aims to provide an up-to-date, consensus-based overview of the 
most extensively utilised clinical outcome measures for MS that could detect changes in levels of 
impairment, compatible with the practicalities and demands of clinical care, detailing their 
relative strengths, and their focus on particular symptom/function domains. In doing so, this 
review addresses current practice and views concerning the most effective instruments currently 
employed for assessing MS symptoms/functionality and treatments.  This review has multiple 
objectives: (1) to survey and critique the measures in common use; (2) to examine the strengths 
and weaknesses of these measures in the context of MS data collection (e.g., their reliability and 
validity for this population); and (3) in the light of these findings to offer a helpful resource for 
clinicians and researchers working in the field of MS to enable them to choose the set of 
measures that are best suited for their particular needs. The study’s outputs will aim to be a 
helpful resource for clinicians and researchers working in the field of MS. 
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Review Method 
Search Strategy 
Search engines and computerised bibliographic databases were deployed to identify papers that 
have used measures of clinical outcomes for MS (PubMed, PsychINFO, Google Scholar, Web of 
Knowledge). In all cases, the search phrases, “clinical-outcome-measures” and “multiple-
sclerosis”, were employed together, using a backward chronological saturation search strategy. 
Such a search strategy moves from the most recent year (2012) backwards, in chronological 
order, through the published literature, year by year. For every article identified, its methodology 
was examined to determine which measures had been used. This process continued until no 
further measures were identified from the search. The ‘saturation principle’ was used to 
determine when to stop (i.e. when no new measures were coming to light).  
 
This method was designed to produce a list of outcome measures that reflects current and recent 
usage. This is important, given the fast-moving nature of medical and health care developments 
as a whole, and in this field, in particular, with many instruments rapidly superseded and 
replaced by alternative measures, or are altered and updated with newer versions.  
 
Validation 
To ensure that there were no major omissions from the initial list of outcome measures, two 
additional search and validation strategies were adopted. Firstly, the full list of instruments, 
derived from the current search, was compared to those listed in a number of recently published 
reviews of the literature on MS outcome measures
20,22,27-30,32-34
. Secondly, the full set of 
measures derived was compared to the list of measures provided by the NICE Guidelines
26
. This 
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rigorous search and validation process identified an initial total of 166 instruments that have been 
employed extensively as MS outcome measures.  
 
 
Refinements 
This extensive list was subjected to two stages of refinement, in order to produce a summary of 
contemporary clinical outcome measures most often used for MS. Firstly, the full list was 
provided to an independent panel of consultant neurologists with expertise in MS, convened by 
the U.K. MS Society, for scrutiny and comment. This process involved discussion of these 
measures, moderated by a member of the MS Society who was independent to the authors of this 
study. The panel members were asked to comment on the full list, and to indicate which 
measures they typically employed for the assessment of MS outcomes. This refinement process 
was directed at developing a much reduced version of this list. This first refinement process 
resulted in 23 measures being identified. 
 
The 23 measures identified as most used in MS clinical contexts, were sent, as part of a 
questionnaire, to 82 U.K. centres involved in the treatment of MS. These centres were asked to 
indicate which of these measures they employed, and whether they used any other measures in 
addition to those listed. The teams who were consulted at each of the treatment sites were 
interdisciplinary, and typically comprised a Consultant Neurologist, a Head MS Nurse, a 
Physiotherapist or a Speech Therapist or an Occupational Therapist. The teams all contributed to 
the questionnaire responses, and the Head MS Nurse usually returned the questionnaire after 
consultation with their other team members. Responses were obtained from 41 centres (50%). 
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These responses indicated that none of the centres used measures that were not already included 
in the shortened list from the expert panel consultation. All of the 23 measures, except for two 
(Brief Repeatable Battery of Neuropsychological Tests, and the Percentage of Patients 
Remaining Relapse Free) were employed by at least one of these centres. There were 21 
measures identified as being in contemporary use for MS clinical outcome assessments. The 
mean use across the centres for any specific scale was 20% of the centres (+ 17%), with the use 
ranging from 2% of the centres employing the least-used measure, to 76% of the centres 
employing the most-used measure (see Figure 1).  
------------------ 
Figure 1 
------------------ 
 
Measurement Scales 
The identified measures were subject to further analysis by searching the literature in order to 
identify their features, and their psychometric properties. The standard types of psychometric 
properties were identified (see Figure 2) to enable the measures to be compared with one 
another. In all cases, at least two independent assessments of these properties were identified 
from the literature, where possible, from sources other than the author. Of the remaining 21 
measures, four were removed. Clinical Relapse Rate/Severity/Time to First Relapse was 
removed, because it could not be considered as a measure with psychometric properties; Quality-
Adjusted Life Years, depends on other measures for its usefulness; and a further two, Evoked 
Response Potential, and Magnetic Resonance Imaging, were generic technologies that 
encompass a wide range of measures, which are not readily susceptible to psychometric analysis. 
                                                                                                       Outcome measures for MS  -   7 
Additionally, details regarding the Fatigue Impact Scale, and its modified version, were merged 
into one for the purposes of this review. 
-------------------- 
Figure 2 
------------------- 
Figure 1 shows the measures categorised by the predominant domains that they address. In 
addition, each instrument is classified as MS-specific or generic, and as clinician-administered or 
patient-completed. Figure 3 shows the psychometric properties, as measured on MS samples, and 
main qualities of each measure.   
----------------------- 
Figure 3 
---------------------- 
 
Physical Disability 
The Modified Ashworth Scale
39,40 
measures muscle spasticity for each joint on a 6-point scale.  
The resulting score has variable inter-rater agreement, some being good (86%
39
), but this 
reliability is better for upper joints (80
.
6%) than for lower joints (63
.
9%)
41,42
. As motor function 
can vary dramatically between extremities within individuals with MS, it makes little sense to 
evaluate the internal consistency of this scale, although some attempted this, and found moderate 
values (0.78
37
). The test has varying test-retest reliabilities, 93
.
4% for upper joints, and 71
.
1% for 
lower joints, with some studies reporting very low test-retest reliability
37
. However, the 
variability of these reliabilities across joints has caused some concern
43,44
. The resulting 
spasticity score has rather poor concurrent validity with similar disability scales, such as the 
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Spasm Frequency Scale
45
, and electromyography
46
, and a poor correlation with the EDSS
37
. 
Upper joints have better concurrent validity than lower joint scores
47
. The variable reliability and 
poor validity have lead some to question its usage for MS
48
, and the modified modified version 
has been produced, which appears to show better psychometric properties in its initial trials
49
. 
 
Expanded Disability Status Scale (EDSS)
50
 is a measure of impairment and impacts of MS, 
which scores disability on a 20-point scale (0 = normal to 10 = death), on the basis of a 
neurological examination. In addition to the overall score, there are also 8 associated functional 
systems assessment scales. There is a patient-rated equivalent, the Patient Determined Disease 
Steps, which is a single-item scale, relating to 8 levels of disability. This is a generic measure of 
disability, but it is mainly used for MS, and it correlates between 0
.
70
51
 and 0
.
93
52
 with the 
clinician-administered EDSS. The EDSS has moderately good reliability characteristics, having 
inter-rater correlations measured as between 0
.
32 and 0
.
76
12
, and 0
.
5 and 0
.
7
53
. It has an internal 
reliability of 0
.
88 to 0
.
96
54
, and test-retest reliability reported as between 0
.
42 and 0
.
66
12
, and 
0
.
61 and 0
.
94
55
. It also has good concurrent validity, in that it correlates well with the Multiple 
Sclerosis Functional Composite score, with measures of disability (0
.
84)
55
, and with physical, but 
not mental, measures of quality of life
12,55,56
. It correlates well with patient-rated measures of 
physical disability
51
. It has poor sensitivity (24%), but good specificity (79%)
57
. However, a 
major drawback is its lack of responsiveness to clinical change (effect size = 0
.
1)
12,58
, being 
better for less severely disabled individuals
59
. In particular, changes in the EDSS score from one 
time to another often fall within the error that would be typically expected on the basis of inter-
rater agreement
60
. To help overcome these problems it has been suggested that two EDSS 
determinations are made prior to intervention, and either the mean value (to increase power) or 
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the lower value (to increase sensitivity) be employed
61
. It is generally agreed that it would need 
substantial modification to be used as a main tool of clinical change
62
, but its widespread use and 
long history mean that some have suggested that it continue to be used as part of a battery of 
assessment tools
22
. 
 
Functional Independence Measure (FIM)
63
 assesses the ability of a patient to conduct routine 
daily activities, also often used for older people and those who have suffered a stroke. The 
instrument contains 18 items, which produce a composite measure of independence when 
assessed: 13 of these items are concerned with motor function (based on the Barthal Index); and 
7 items are related to cognitive function. A shorter version, the alpha-FIM, is available, which 
has only 6 items
64
. All items are rated on a 1 (total assistance required) to 7 (full independence) 
scale. It can be combined with the Functional Assessment Measure (FAM), which adds 12 items 
concerned with cognition, similarly completed by a health care professional
65
. The FIM has an 
inter-rater reliability of between 0
.
83 and 0
.
99
66-68
, although this is greater for the motor items 
(0
.
95) than for the cognition items (0
.
78)
67
, suggesting that the FIM should not be used without 
the FAM for assessment of cognitive independence
69
. The FIM also has good internal reliability 
(0
.
94
66
, 0
.
98
12
). It has good test-retest reliability, measured as between 0
.
95
67
 and 0
.
99
12
. It has 
good concurrent validity with both the EDSS
66
, and the Barthal Index
70
. As the FIM was heavily 
based on the Barthal Index for motor items, this is not surprising.  However, the validity is less 
good for the neurological aspects that it measures. There are no data for its sensitivity and 
specificity. A key criticism is that it is not responsive to change
12
, with effect sizes of between 
0
.
3
69
 and 0
.
46
12
, and lower for the cognitive items. This lack of responsiveness to change may be 
the result of floor and ceiling effects
71
. 
                                                                                                       Outcome measures for MS  -   10 
 
Guy's Neurological Disability Scale (GNDS)
72
 is a measure of general clinical disability, and 
asks the patient to assess their current clinical state over the last month (a patient self-
administered version is also available
73
. It gives an overall measure of disability and sub-
scores covering 12 domains. It has an internal reliability of around 0.80
72,74
. This instrument has 
a very good test-retest reliability of over 0
.
96
72,75
 for the overall score, and of 0
.
68 to 0
.
99 for the 
sub-scales. However, it has mixed results in terms of concurrent validity; correlating 0
.
64 with 
the EDSS, and 0
.
76 with the Barthal Index
75
.  As would be predicted, it has lower correlations 
with scales that do not measure physical disability
76
. There are no data on its sensitivity or 
specificity. The GNDS appears to be reasonably responsive (effect size, 0
.
58)
12
, although lower 
effect sizes have also been noted
77
. Its duration of administration, and its uncertain 
responsiveness, means it tends to be used largely in clinical practice, rather than for trial 
purposes
27
. 
 
Multiple Sclerosis Functional Composite (MSFC)
78
 assesses the level of impairment across 
three domains at the time of testing (i.e. leg function is assessed by a 25-feet walking task, arm 
function by the nine-hole peg test, and cognitive function by use of the paced auditory serial 
addition test). The assessment provides analysis of the above three aspects of functioning, as well 
as an overall composite measure (although this summary measure has been critics as being 
‘abstract’ and difficult to interpret clinically22. The measure has an inter-rater reliability of 0.9579 
to 0
.
96
80
 for the composite score, and 0
.
93 to 0
.
99 for the components
80
. It has an internal 
reliability of 0
.
97 for the overall composite score
81
. The test-retest measures are good, ranging 
between 0
.
87
56
 and 0
.
90
82
 for the overall score, and 0
.
93 to 0
.
98 for the subtests
80
. However, there 
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are some practice effects that are particularly noticeable on the first few applications
82
. It has 
good concurrent validity scores with a range of other measures of disability: 0
.
80 with the 
EDSS
83,84
; and it correlates well with MRI measures of brain atrophy
79
. It shows weaker 
association with measures of emotional functioning
79
.  It has moderate sensitivity (51%)
79
, and it 
is moderately good at predicting both disability
85
 and MRI results
86
. It has a strong (86%) 
specificity
79
. Its responsiveness is measured as being between 0
.
62 and 0
.
71 in terms of the area 
under the curve in the ROC
87
, and has a reported effect size of 0
.
50, although responsiveness to 
clinical trails can be compromised by the absence of a test for vision
22
, and this value is better for 
the leg function than for the upper limb and cognitive measures
56
. Moreover, the responsiveness 
of the cognitive component is not strong
88
, and this should not be relied upon as a sole measure 
of cognitive change for MS. As a result many have suggested replacing the existing cognitive 
component (the paced auditory serial addition task), with the symbol digit modalities test, to 
enhance the test
22
.  
 
Multiple Sclerosis Walking Scale-12 (MSWS-12)
77
 assesses patient-reported disruption to their 
walking, and its 12 items measure patient-perception of their walking quality during the past 2 
weeks. This measure has a strong internal reliability of 0
.
97
89-91
, and good test-retest reliability 
ranging from 0.86
91
 to 0
.
96
89
, and over 0
.
78 for the individual items
77
. It has good concurrent 
validity, as it correlates 0
.
80 overall with the EDSS (although this relationship is mainly driven 
by strong correlations at lower levels of disability), and 0
.
77 with the MSIS-29 physical scale
90
, 
and 0
.
82 with physical scales from the SF-36
89
.  However, its correlation with accelerometry 
scores are moderate, and range from 0.38
92
 to 0
.
70
93
, as are its correlations with other objective 
measures of walking
94
. There are no data on its sensitivity and specificity.  A strong feature of 
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the tool is that it has good levels of responsiveness
35
, with effect sizes being greater than 
1
.
00
77,95
, but the variance between differently disabled groups may make it less than optimal for 
comparing between samples
96
.  
 
Cognitive Impairment 
Mini-Mental State Examination (MMSE)
97
 screens for dementia and cognitive impairment at 
the time of testing. It comprises 11 items that measure a number of domains (a standardised 
version exists, but this has not been tested for MS
98
). It has a good internal reliability of 0
.
89 to 
0
.
95
97
, but variable test-retest reliability, ranging between 0
.
65 and 0
.
89
97
. It does display some 
moderate concurrent validity – it correlates 0.78 with the verbal IQ score from the WAIS97. 
However, it has been noted that it is not well suited for the patterns of disability seen in MS
99
, 
and it has poor sensitivity for this population of between 28%
100
 and 36%
101
. It does have good 
specificity (89%)
101
, but poor, and unreliable, responsiveness, given its weak test-retest 
reliability
102
. Given the latter problems, some have recommended that it not be used for people 
with MS
103
, and it is more commonly employed as part of a battery of tests to describe the 
sample characteristics, rather than to assess change due to an intervention
104
. 
 
Psychological/Emotional 
Beck's Depression Inventory (BDI-II)
105,106
 measures depression over the last week. There are 
21 items, each rated on a 4-point scale, relating to symptoms of depression, which gives an 
overall score. It has an internal reliability score for people with MS of between 0
.
86
107
 and 
0
.
94
108
. It has a test-retest reliability of 0
.
93 across people with a range of disorders
105
. It has 
good concurrent validity for MS
109
, and correlates well (0
.
65) with psychiatric ratings of 
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depression, and with the SF-20 sub-scales
108
, and 0
.
71 with the Hamilton Depression Scale
105
. It 
has between 81%
110
 and 84%
111 
sensitivity, and 70% specificity, in all phases of the disease
111
. 
Its responsiveness is also reasonable
109,112
. However, there is some discussion about whether 
some of the items from the BDI-II should be removed for use with MS, as they overlap with 
some of the symptoms and impacts of MS
107,113
. 
 
General Health Questionnaire (GHQ)
114
 is used for assessing general psychiatric problems over 
the prior ‘several weeks’, and it comes in many versions, including: the GHQ-12 (which gives an 
overall score); the GHQ-28 (which gives scores for somatic problems, anxiety, social 
dysfunction, and severe depression, as well as an overall score); the GHQ-30 (which gives an 
overall score); and the GHQ-60 (which gives an overall score). The most used for MS are the 
GHQ-12 and GHQ-28, being the shortest versions. The GHQ-12 has an internal reliability of 
0
.
91
115
, and the GHQ-28 has an internal reliability of 0
.
90
116
. The GHQ-28 has a test-retest 
reliability of 0
.
69 in a general population
116
. There are reports of a retest/practice effect 
impacting on the score
117
. The GHQ-28 has a moderate concurrent validity (0
.
44 to 0
.
66) with a 
range of health measures
76
, and correlates 0
.
83 with the present state examination
118
. There are 
mixed reports about the sensitivity of the GHQ-12, these being 36% to 67%
76
 or 72% to 92%
119
, 
the GHQ-28 being reported to have better sensitivity
120
, and is recommended as one of the stem 
tools for identification of depression in chronic illness
121
. The GHQ-12 has good specificity, 
being measured as over 74%
76,119,120
. Reports on the responsiveness of the GHQ-12 are also 
mixed, varying from effects sizes of 0
.
15
122
 to 0
.
51
123
. 
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Hospital Anxiety and Depression Scales (HADS)
124
 assess levels of anxiety and depression, 
excluding somatic symptoms to avoid overlap with any physical symptoms of the patient. 
Originally designed for use by hospital general medical outpatients, it has since been widely 
employed in primary care settings, and also in on-line surveys
125
, and contains 14 items (7 for 
anxiety and 7 for depression), that relate to the last week. Patients are recommended not to take 
very long to respond, as their immediate replies should better reflect their actual state than more 
considered reactions
124
. This instrument has excellent reliability, having an internal reliability of 
0
.
83 for anxiety
21,126
, and of 0
.
81
126
  to 0
.
82
21
 for depression. Its test-retest reliability is 0
.
89 for 
anxiety and 0
.
86 for depression
127
. It has reasonable concurrent validity correlates between 0
.
49 
and 0
.
83 with similar instruments
128
, and 0
.
62 for anxiety, and 0
.
55 for depression, with the 
appropriate Beck scales
76
. It has mixed reports concerning sensitivity, it has 88
.
5% sensitivity for 
anxiety, and a 90% sensitivity for depression, when tested against objectively rated symptoms
129
, 
but between 29% and 46% for anxiety, and 25% and 46% for depression, when measured against 
other self report scales
76
. Its specificity is excellent, being measured as between 80% and 90% 
for anxiety, and 84% to 90% for depression, regardless of the anchor measure used
76,129
. 
However, the anxiety scale tends to be more sensitive to General Anxiety Disorder than to other 
forms of anxiety
129
. 
 
Quality of Life 
EuroQol-5 Dimensional Questionnaire (EQ-5D)
130
 is a measure of the impacts of disease on 
various aspects of health. There are 5 specific, Likert-type, questions addressing the patient’s 
state on the day of assessment (plus optional questions relating to socio-economic variables). It 
has reasonable test-retest reliability reported as 0
.
63-0
.
80
131
, and 0
.
81
132
. It has reasonable 
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concurrent validity, correlating 0
.
70 with the SF-60
132
, and 0
.
55-0
.
81 with a range of similar 
generic quality of life instruments
12
.  However, its relationship with EDSS scores in MS are 
uncertain
133
, and it does not correlate with objective measures of health and functioning
134
. It is 
not regarded to have sensitivity for MS
76
, and the absence of a fatigue score is an issue in this 
regard
135
, and there are no direct specificity data. Its responsiveness is less than that of other 
instruments
12
, with some ceiling effects and with 40% of severely disabled individuals likely to 
omit the items relating to physical status
132
. This measure is considered good for population 
description, but it may be too insensitive for measuring individual changes.  Although it is 
commonly used for cost estimates in health-economics
136
, some have suggested that disease-
specific tools, such as the MSIS-29, are more sensitive in this context
137
. 
 
Fatigue Impact Scale and Modified (FIS/MFIS)
138,139
 measures the impact of fatigue on daily 
life over the last 4 weeks. This instrument comprises 40 items, and gives an overall fatigue 
impact score and three sub-scales.  (The 21-item MFIS
139
 is a reduced version of the FIS, taking 
5 to 10 minutes to complete, giving an overall score and three subscales; an even briefer 5-item 
version takes 2 to 3 minutes to complete). The FIS has good indicators of overall internal 
reliability of 0
.
98
138
, and 0
.
85
140
, with the individual sub-scales all having internal reliabilities of 
over 0
.
87.  The overall MFIS score has an internal reliability measured from 0
.
81
139
 to 0
.
92
141
, 
with sub-scales raging between 0
.
88 and 0
.
92
141
. The test-retest reliabilities of the overall FIS 
score is measured as between 0
.
81
142
 and 0
.
93
122
, with the sub-scales ranging from 0
.
68 to 0
.
85 
138,142
. For the MFIS, the overall test-retest reliability varies between 0
.
82-0
.
85
141,143,144
. There is 
moderate concurrent validity of the FIS with the SF-36
142
, and between the MFIS and the Fatigue 
Severity Scale (0
.
66)
144
, 0
.
68 
145
. In terms of its sensitivity, 78% of people with MS are identified 
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correctly by the FIS
138
, with the MFIS have a greater then 90% sensitivity
146
. There are no data 
on specificity for the FIS, but the MFIS has greater than 90% specificity
146
. The FIS has a greater 
than 0
.
7 effect size in terms of its responsiveness
147
, with the MFIS having effect sizes of greater 
than 0
.
5
148,149
, but it is not greatly responsive over short periods of time
144
. Recently, the 
usefulness of the overall fatigue impact score of these scales has been called into question, 
although the sub-scales, used on an individual basis, are considered to be safe
150
, and, as a 
result, the 22-item Unitary FIS (U-FIS) has been developed to give an overall fatigue score
151
. 
Nevertheless, this is the tool recommended to assess fatigue-related quality of life
152
. 
 
Leeds Multiple Sclerosis Quality of Life Scale (LMSQoL)
153
 is a measure of the impact of MS 
on quality of life at the time of completion. This scale has 8 items, each scored on a 4-point 
Likert-type scale, and it gives an overall index of quality of life. The scale has a good internal 
reliability, being reported as between 0
.
71 and 0
.
86
21,76,153
, and good test-retest reliability of 
0
.
85
153
. While there are some reports of moderate concurrent validity: 0
.
68 with the SF-36, and 
0
.
83 with measures of well-being
153
, and it correlates with diary reports of the impact of MS
154
, 
recent questions have been raised about its validity when compared to the MSQoL
76
. There are 
no data for its sensitivity and specificity. It has moderate responsiveness, having reported effect 
sizes of 0
.
34
76,155
, and 0
.
45
156
, with little sign of floor or ceiling effects
157
. 
 
Multiple Sclerosis Impact Scale (MSIS-29)
158
 measures the impact of MS on daily living over 
the preceding 2 weeks, rather than on the resulting quality of life. Its 29 items produce an overall 
score and sub-scales relating to both physical and psychological domains.  The overall score is 
considered to be of debatable use
159
. The internal reliability of the two sub-scales is very good 
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ranging from 0
.
88 to 0
.
96 for the Physical, and 0
.
85 to 0
.
91 for the Psychological
158,160-162
, as are 
their test-retest reliabilities, which range from 0
.
86 to 0
.
94 for the Physical, and from 0
.
81 to 0
.
87 
for the Psychological
158,161-163
. The score correlates moderately well with similar instruments, 
giving this scale reasonable concurrent validity: the Physical scale correlates 0.66 with the EDSS 
and 0
.
69 with the GNDS
162
, and greater than 0
.
5 with other measures of disability
160,164
; the 
Psychological scale correlates greater than 0
.
6 with other scales measuring mental functioning
160
. 
The sensitivity is good
137
: 78% for the Physical scale
161,165
; and 73% for the Psychological 
scale
161
. Reports on its specificity are mixed, some results being good (greater than 80% for both 
scales
161
, but some being only moderate (51% for the Physical scale
165
. The responsiveness of 
the Physical scale, which is good (0
.
82 effect size), is better than that of the Psychological scale, 
which is moderate (0
.
66 effect size)
122
. The area under the curve in its ROC is good when 
anchored against the EDSS, 0
.
72
165
, but lower values have been reported
166
. 
 
Multiple Sclerosis Quality of Life-54 (MSQoL-54)
157
 assesses the quality of life of individuals 
with MS over the last 4 weeks (the 54 items include the 36 items from the generic SF-36 
questionnaire). This tool gives an overall score for quality of life, comprising two health sub-
domains (Physical and Mental). The overall score has an internal reliability measured as between 
0
.
84
167
 and 0
.
96
168
, with the sub-scales having internal reliabilities ranging from 0
.
75 to 0
.
96
157
. 
The test-retest reliability coefficients range between moderate 0
.
61 and good 0
.
96
157,169
. The 
overall measure correlates moderately with MS symptoms measured by the ICD
167
, it also 
correlates moderately with the EDSS and MSFC (0
.
49 to 0
.
67), and with the Leeds MS QoL 
scale
170
. Both the Physical and Mental Health sub-scales correlate well with the Fatigue Severity 
Scale
171
. There are no data on its sensitivity and specificity, although the addition of 18 MS-
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specific questions to the generic SF-36 should improve these properties relative to the generic 
form
157
. Reports on its responsiveness are mixed
172
 with effect sizes of over 0
.
7 for the physical 
scales, and between 0
.
57 and 0
.
7 for the mental scales
166
, while other reports on responsiveness 
have been poor
123
. There has been some criticism of potential floor and ceiling issues that may 
limit its usefulness as an outcome measure
28
. 
 
Short Form SF-36 Health Scale
173
 measures the impact of a disorder on the functioning of an 
individual over the last 4 weeks. Derived from the GHQ-28
114
, this form contains 36 items, 
producing an overall score relating to impacts on health, as well as two sub-scales (physical 
health and mental health). The overall scale has an internal reliability of 0
.
67 to 0
.
94
173
, with the 
sub-scales ranging between 0
.
77 and 0
.
96
54,174
. The test-retest score results are mixed, and are 
between 0
.
64 and 0
.
96 for the subscales
174
. However, there have been recent suggestions that the 
psychometric properties of the two main scales (physical and mental) are not as good as the 
overall score, or those of the sub-scales on which they are based
158
. It has moderate concurrent 
validity (0
.
6) with symptom severity
174
. The physical scale has moderate correlations (0
.
6) with 
the FIM and the EDSS, and the mental sub-scale correlates 0
.
5 with the GHQ
123,133
. It has 
moderate sensitivity for body functions and activities in MS
175
, but there are no data on its 
specificity. The effect sizes show poor responsiveness, ranging from 0
.
01 to 0
.
30
123,176
.     
 
Discussion 
The findings suggest a relatively wide range of instruments are commonly used in MS 
assessment, and those employed measure many varied MS symptoms/functions, and reflect the 
need to capture the diverse nature of this disorder’s symptomatology and impact on a person’s 
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functioning. These scales evaluate the symptoms/functioning in each of four broad categories: 
physical (e.g., physiological, fatigue, movement); cognitive (e.g., memory, attention); 
psychological and emotional (e.g., depression, anxiety); and quality of life (i.e. impacts of the 
symptoms/functioning on daily life and living). Naturally, there is overlap across the aspects that 
an individual scale measures, and between these broad categories. It is not always 
straightforward to ascertain which domain a questionnaire indexes; the content of some measures 
covers more than one domain. For instance, there can be difficulty discriminating the direct 
symptoms of MS and their effects on functioning from the impacts of those symptoms/functions 
on daily life.  Some aspects of MS (e.g., gait, pain, incontinence, depression) may be physical or 
psychological problems and also quality of life problems, and it is not necessarily easy to divide 
them into separate domains. The impact of physical issues on an individual (e.g., producing 
depression) is not readily distinguishable from their impacts on what an individual can or cannot 
do (i.e. their quality of life). In developing test-sets, attention should be paid to these issues. 
However, it is useful to compare the assessment tools along the four dimensions, to allow 
comparison between the measures, and to develop appropriate MS assessment sets (see Figures 1 
and 3). 
 
In terms of physical symptoms, the measures that address these mainly focus on mobility and 
motor function, and deal with central nervous system damage. The majority of such tools are 
clinician-administered (Modified Ashworth Scale, EDSS, FIM, MSFC), with only two such 
scales being patient-completed (GNDS and MSWS-12). This may reflect the facts that these 
symptoms/functions are observable, and measurable, by the clinician, and that a patient’s 
judgement of their physical symptoms and functioning may be confounded with other factors 
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(e.g., mental state). Of the clinician-administered scales, three deal largely with mobility and 
motor function (Ashworth, EDSS, and MSFC). All of these give reliable measures of the present 
levels of disability. The patient-completed scales concerning motor symptoms/functioning (some 
aspects of the GNDS, and the MSWS-12) give reliable measures of current levels of disability, 
although not as reliable as the clinician-administered scales. However, the clinician-administered 
scales (especially the EDSS) suffer from a common problem of not being particularly responsive 
to change in disability status, possibly resulting from the nature of the physical problems 
themselves, in that, once mobility has been impaired, it may not then readily return to its former 
unimpaired state (especially in some types of MS). The patient-completed scales appear more 
responsive to change in disability status, but it is not clear whether this reflects their measure of 
the disability itself, or a person’s perception of their disability, which may be different, and the 
latter may be responsible for responsiveness to change. In this context, it is informative to 
consider current models of disability. For example, the World Health Organisation’s (WHO) 
International Classification of Functioning, Disability, and Health (ICF) acknowledges that 
‘disability’ is a constructed experience – that is, the person’s own perception of their 
symptoms/functioning, in addition to any objective assessment of those issues, is a prime aspect 
of disability. In addition, the literature suggests that better personal perceptions of health are 
stronger predictors of confidence regarding a person’s involvement and participation in their 
community (which is also a key element defining disability in the WHO's ICF framework). 
 
There are only two clinician-administered measures that deal with cognitive impairments (e.g., 
memory, attention, problem solving, information processing), which are the MMSE, and one 
component of the MSFC. However, these measures are rather poor, both in terms of their 
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psychometric properties, and in their lack of sensitivity to MS cognitive impairments. In 
addition, neither of these captures the potential range of impairments, focusing only on very 
specific and limited tests. These criticisms are also potentially true of the patient-completed 
measure of cognition contained in the GNDS. The measurement of this domain, by the 
commonly employed scales, is potentially the weakest, and some consideration should be given 
to employment of better validated tests of cognitive function, or, at least, some of their sub-
scales, such as the WAIS. 
 
A third area of symptomatology or functioning that some of these instruments address is the 
psychological and emotional impacts of MS. Some of these symptoms/functions may result from 
CNS damage, but many will also result from the impact of MS on the ability of a person to 
conduct activities in which they wish to engage. Due to the subjective nature of these symptoms 
and their impacts on functioning, all of the scales that assess these aspects are patient-completed. 
In terms of depression, both the BDI and the HADS have very good psychometric properties for 
MS. The HADS has a slight advantage in that it is shorter, and it measures both anxiety and 
depression. The EQ-5D, GHQ-28, GNDS, and the SF-36, all contain measures of psychological 
function, that correlate with the BDI and HADS, but they are not necessarily related to clinical 
definitions of depression, and also reflect the impacts of these problems, rather than the problems 
themselves. In terms of fatigue, the FIS and MFIS are fatigue-specific instruments, of which the 
MFIS is thought to have an advantage psychometrically, especially when used for the separate 
impacts of fatigue on physical and mental functioning. The only measure that deals specifically 
with pain symptoms is the EQ-5D, although other measures assess the impact of pain on limiting 
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activities. All of these measures have reasonable psychometric properties, but not all of them are 
MS-specific, and this may merit consideration. 
 
In regards to quality of life, the psychometrics of almost all of these measures are reasonably 
robust, although not all of these measures are MS-specific. Typically, it is the case that, the 
longer the measure, the better the psychometric properties. Most of these longer measures give 
an index of both physical and mental quality of life functioning. Of the nine quality of life 
measures (EQ-5D, FIS, GHQ, LMSQoL, MFIS, MSIS-29, MSQoL-54, SF-36), four appear to 
offer very good coverage of quality of life issues, as well as having excellent psychometric 
properties (GHQ, MSIS-29, MSQoL-54, SF-36). Of these, the MSIS-29 is MS-specific, the 
MSQoL-54 has some MS-specific questions, and also encompasses the generic SF-36. However, 
in choosing an appropriate questionnaire, issues regarding the MS-specificity of a scale’s items 
should be considered.  It has been recommended
130
 that the MFIS is used, when working with 
people with MS, as it was developed on an MS population, however, the MSIS-29 is MS-
specific, and this measure offers better psychometric properties than the MFIS. The generic 
GHQ and the SF-36 do similar things to one another, as the SF-36 is derived from the GHQ, and 
so would not be employed together. The MSQoL-54 is MS-specific, and encompasses the SF-36, 
and it is similar, in itself, to the MSIS-29, which is shorter.  So a choice may be between using 
the GHQ and the MSIS-29, or using the MSQoL-54. An ideal approach is to choose a set of tests 
in which there is some overlap across the various measures; for example, when assessing quality 
of life, it would be desirable to use measures that examine the impact of physical 
symptoms/functioning in conjunction with other measures that examine the objective physical 
symptoms/functioning. In addition, a generic HRQoL measure (such as the EQ-5D) should be 
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included in any set of outcome measures to enable comparison with population norms, with other 
conditions, and to facilitate health economic analyses using QALYs, which generic HRQoL 
measures can help to produce.   
 
In summary, the key to better assessment of MS is to develop tailored balanced sets of measures 
that are both complementary and comprehensive. Given the multiple symptom/function domains 
of MS, which vary in quantity and quality across patients, it would be very difficult to prescribe 
a single recommended battery of measures to detect changes in impairment; these would vary 
according to the needs of the clinician, researcher, or patient. Such assessment sets should 
include measures for each of the four areas discussed above, with consideration to time 
efficiency, minimising replication or scale redundancy, and not fatiguing the patient. Provided 
here is a resource from which suitable sets of commonly-used measures can be selected, 
determined by the specific requirements of each situation. This review could aid such 
developments, and be a useful resource in itself.  
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Figure 1: Psychometric characteristics 
 
Property Measured Assesses 
Internal Reliability Chronbach’s Alpha The degree to which all items are 
related to one another 
Test-Retest 
Reliability 
Correlation between test 
administered at two separate 
times 
The freedom from unsystematic error 
over time 
Concurrent 
Validity 
Correlation between measure 
and other measures in the 
area 
Whether the scale compares well with 
other similar tools 
Sensitivity Test-identified positives 
divided by all actual positives  
The degree that the measure identifies 
individuals with the disorder (true 
positives) 
Specificity Test-identified negatives 
divided by all actual 
negatives 
The degree to which the measure does 
not identify people without the disorder 
(true negatives) 
Responsiveness Effect sizes, or area under the 
receiver operating 
characteristics curve 
The ability to detect changes in the 
measure over time 
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Table 2:  Characteristics of measures. 
 
Measure Generic or 
MS Specific 
Clinician 
Administered 
or Patient 
Completed 
Approximate 
Length of 
Time to 
Administer 
or Complete 
Domains Covered 
Modified 
Ashworth  
Scale 
Generic Clinician Short 
(depending 
on number of 
joints 
assessed) 
Physical Disability: 
Muscle spasticity, joint by joint 
Beck  
Depression 
Inventory 
Generic Patient 10 min Psychological/Emotional: 
Symptoms of depression (e.g., hopelessness, 
irritability, guilt, and somatic problems) 
Euro Qol - 5 
Dimension 
Questionnaire 
Generic Patient 5 min Quality of Life: 
Mobility, self-care, usual activities, pain, 
anxiety/depression, and general health. 
Expanded 
Disability Status 
Scale 
Generic 
(mainly used 
for MS) 
Clinician 
administered 
and rated 
Variable 
(depending 
on 
neurological 
examination) 
Physical Disability: 
Impairment and disability (with 8 additional 
scales: pyramidal, cerebellar, brainstem, 
sensory, bowel and bladder, visual, cerebral, 
and other functioning) 
Fatigue Impact 
Scale and 
Modified 
Generic 
(developed 
on an MS 
population) 
Patient 20 min Quality of Life: 
Overall impact of fatigue, and sub-scales 
relating to the: physical, cognitive, and 
psychosocial, impacts of fatigue 
Functional 
Independence 
Measure 
Generic Clinician or 
trained 
layperson 
30 min Quality of Life: 
Independence and ability of a patient to 
conduct routine daily activities concerned 
with motor function (e.g., self-care, sphincter 
control) and cognitive function (primarily 
social and communication function) 
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General  
Health 
Questionnaire 
Generic Patient Up to 8 min 
(depending 
on version 
used) 
Psychological/Emotional: 
General psychiatric problems (GHQ-28 scores 
somatic problems, anxiety, social dysfunction, 
and severe depression) 
Guy’s 
Neurological 
Disability Scale 
MS Specific Clinician or 
Patient 
30 min Physical Disability: 
Overall disability (12 sub-scales: cognition, 
mood, vision, speech, swallowing, upper and 
lower limb function, bladder and bowel 
function, sexual function, fatigue, and other) 
Hospital Anxiety 
and Depression 
Scales 
Generic Patient 5 to 10 min Psychological/Emotional: 
Anxiety and Depression 
Leeds 
Multiple 
Sclerosis QoL 
Scale 
MS Specific Patient 5 min Quality of Life: 
Overall index of quality of life, mostly 
focuses on fatigue and social issues 
Mini Mental 
State 
Examination 
Generic Clinician 20 min Cognitive Impairment: 
Cognitive impairment across a number of 
domains (e.g., attention, memory, orientation, 
arithmetic) 
Multiple 
Sclerosis 
Functional 
Composite 
MS Specific Clinician Variable 
(depending 
on disability 
level) 
Physical/Cognitive Impairment: 
Impairment across 3 domains (leg function, 
arm function, and cognitive function) 
Multiple 
Sclerosis Impact 
Scale 
MS Specific Patient 10 min Quality of Life: 
Impact of MS on daily living on both physical 
and psychological aspects 
Multiple 
Sclerosis 
QoL-54  
MS Specific 
(generic 
component) 
Patient 11 to 18 min 
according to 
Vickrey et al. 
1995 (at least 
30 min 
according to 
Bandari et 
Quality of Life: 
Overall quality of life with two domains 
Physical Health (physical function, health 
perceptions, energy/fatigue, role limitations - 
physical, pain, sexual function, social 
function, and health distress); and Mental 
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al., 2010) Health (health distress, overall quality of life, 
emotional well-being, role limitations - 
emotional, and cognitive function) 
Multiple 
Sclerosis 
Walking Scale 
MS Specific 
(has been 
used for other 
disorders) 
Patient 5 min Physical Impairment: 
Disruption to walking and walking quality 
Health Scale 
Short 
Form-36 
Generic Patient 10 to 15 min 
 
Quality of Life: 
Overall impact of a disorder on functioning 
(with sub-scales for physical health and 
mental health, which, themselves, are based 
on a number of sub-scales that measure: 
physical functioning, role limitation, pain, 
general health, vitality, social functioning, and 
mental health. 
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Table 3: Quality of the psychometric properties of measures. 
 
Measure Internal 
Reliability 
Test-Retest 
Reliability 
Concurrent 
Validity 
Sensitivity Specificity Responsive-
ness 
Modified 
Ashworth  
Scale 
      
Beck  
Depression 
Inventory 
      
Euro Qol - 5 
Dimension 
Questionnaire 
      
Expanded 
Disability Status 
Scale 
      
Modified/ 
Fatigue Impact 
Scale 
      
Functional 
Independence 
Measure 
      
General  
Health 
Questionnaire 
      
Guy’s 
Neurological 
Disability Scale 
      
Hospital Anxiety 
and Depression 
Scales 
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Leeds 
MS QoL 
Scale 
      
Mini Mental 
State 
Examination 
      
MS 
Functional 
Composite 
      
Multiple 
Sclerosis Impact 
Scale 
      
Multiple 
Sclerosis 
QoL-54  
      
Multiple 
Sclerosis 
Walking Scale 
      
Health Scale 
Short 
Form-36 
      
 
 
 
 
Key: 
 Not Applicable 
 Poor (< 0.4) 
 Moderate (0.4-0.7) /Mixed or Varied Values/Some Caution Required 
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 Good (> 0.7) 
 No Data Available 
 
 
 
 
 
 
 
 
